# Hepatitis B Vaccination Policy Changes May Increase Chronic Infection Rates New computer modeling suggests delaying infant vaccinations could lead to a significant surge in cases. - **Source:** [TIME](https://time.com/) - **Published:** 2026-10-19 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/cb6361cd-8a82-4310-afa6-e5ee2b2171f6 ## Shift in Vaccination Guidelines In December 2025, the CDC shifted from universal birth-dose recommendations for Hepatitis B to a shared decision-making model for infants born to negative-testing mothers. This policy allows parents and clinicians to delay the initial dose until two months of age, departing from the standard practice established in the United States since 1991. ## Modeling Potential Infection Surges A study published in the Annals of Internal Medicine utilized computer simulations to project infection outcomes over twenty years. Researchers modeled a cohort of 3.6 million children to determine how varying vaccination rates and timing affect chronic Hepatitis B prevalence, specifically comparing the previous birth-dose standard against the new flexible decision-making framework. ## Projected Impact of Lower Uptake The simulation indicates that if vaccination rates drop to 26% under the new shared decision-making model, chronic Hepatitis B cases could rise by 225%. Even with a higher 75% uptake at two months, delaying the first dose still results in a 19% increase in chronic infections compared to the universal birth-dose strategy. ## Clinical and Legal Challenges The American Association of Pediatrics maintains its recommendation for universal birth-dose vaccination for all infants. Consequently, 15 states have initiated lawsuits against the administration regarding these schedule changes. Researchers argue that these policy shifts ignore established clinical evidence regarding the efficacy of early intervention in preventing lifelong chronic liver conditions. ## Long-term Public Health Risks Chronic Hepatitis B infections acquired in infancy carry a 25% lifetime risk of developing liver cancer. Because the virus is often asymptomatic until liver failure or malignancy occurs, researchers warn that annual cohorts of missed vaccinations will compound over time, creating a significant, preventable burden on families and the broader healthcare system. ## Economic Consequences of Delay Beyond clinical outcomes, economic modeling highlights the financial strain of shifting vaccination timelines. One study found that delaying the first dose by two months incurs an additional $16.4 million in healthcare spending related to new infections. This cost persists even if children eventually receive the vaccine, underscoring the inefficiency of delayed immunization schedules. ## Necessity of Screening Protocols Recent studies suggest that if birth-dose vaccination is abandoned, the healthcare system must significantly increase screening for pregnant women to mitigate infant infection risks. Without universal vaccination at birth, the reliance on maternal screening becomes a critical, yet potentially insufficient, mechanism to prevent vertical transmission from mother to child during birth. ## Evidence-Based Policy Implications Researchers emphasize that decades of clinical trials have already validated the efficacy of the birth-dose approach, rendering further human testing unnecessary. The current modeling provides essential evidence to inform policy debates, illustrating that reverting to older, less effective vaccination strategies poses measurable risks to public health and long-term medical expenditure. ## Sources covering this story - https://time.com/article/2026/10/19/hepatitis-b-vaccine-recommendations-study/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._